Dr Reddys to sell two brands, Combihal and Daffy to Mankind Pharma

Written by Ruchika Sharma Published On 2022-02-16T17:34:12+05:30 | Updated On 16 Feb 2022 5:34 PM IST

Dr Reddys to sell two brands, Combihal and Daffy to Mankind Pharma

The entire integration and transition of the brands is expected to be completed by March 2022.

New Delhi: Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy's Laboratories to acquire two brands -- Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising bar for infants.

Mankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent.

The acquisition of the product is expected to strengthen the company's presence in the inhalation respiratory market segment, Mankind Pharma said in a statement.

The total market for Daffy is valued at Rs 1,000 crore growing at 18 per cent, he added.

Read also: Mankind pharma Launches new critical care division

"We believe these brands have adequate potential to grow in the Indian market and the best part of the acquisition is that both these brands perfectly fit in our portfolio, and provides us an opportunity to grow and build the respiratory and dermatology business further," Mankind Pharma President Atish Majumdar noted.

As per the terms of the definitive agreement executed between the companies, Mankind Pharma will take over the manufacturing, marketing and distribution of both the products in India.

The entire integration and transition of the brands is expected to be completed by March 2022.

Read also: Dr Reddy's to now sell Novartis top brand Voveran

Mankind Pharma is the fourth largest pharmaceutical company in India headquartered in New Delhi, India. Its products range from Pharma, OTC and FMCG brands like Manforce Condoms, Unwanted 72, Prega News, Gas-O-Fast, Health OK Tablets, Acnestar Gel, Betakind Gargle and many others.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.

mankind pharmamankind pharma newsdr reddy's labsdr reddy's labs newscombihaledaffyasthma

Source : with inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751